- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07594327
Quality of Life and Sexuality After Pelvic Exenteration for Gynecologic Cancer
Pelvic Exenteration as a Curative Option in Recurrent Gynecological Cancer: Oncological Outcomes and Impact on Quality of Life and Sexuality
Pelvic exenteration is an exceptionally extensive and very rare surgical procedure, most commonly used in the treatment of locally recurrent cervical cancer among gynecological malignancies. It is typically performed with curative intent when no other treatment options remain feasible.
The aim of this study is to examine the quality of life and sexuality of patients who have undergone pelvic exenteration.
This observational cross-sectional study utilizes internationally validated questionnaires assessing quality of life and sexual function: EORTC QLQ-C30, EORTC QLQ-CX24, and PISQ-12.
The findings of this study will provide important guidance for the selection and planning of pelvic exenteration. Improved understanding of postoperative quality of life will support patient selection and enable more comprehensive and individualized patient counseling.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
The investigators will invite living patients who have undergone pelvic exenteration for gynecological cancer at Tampere University Hospital since January 1, 2000, to participate in the study, provided that at least six months have elapsed since the surgery.
The patients are first contacted by telephone to inform them about the study. The investigators will then send an information letter regarding participation, along with questionnaires assessing quality of life and sexuality. There are 21 living patients, most of whom have had cervical cancer. Particular interest will be given to patients who have undergone neovaginal reconstruction, and additional sexuality-related questions have been developed specifically for these patients.
In addition, the medical records of all patients who have undergone pelvic exenteration for gynecological cancer since January 1, 2000, are retrospectively reviewed. Oncological outcomes after pelvic exenteration, factors affecting prognosis, and postoperative complications are assessed.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studie Locaties
-
-
-
Tampere, Finland
- Tampere University Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- patient age over 18 years
- a diagnosis of gynecologic cancer
- having undergone exenteration surgery on or after January 1, 2000 (at least 6 months prior)
- the ability to read and write Finnish
Exclusion Criteria:
- cognitive and/or neurological disease that affects physical functioning and may therefore influence sexual functioning or make it difficult to respond to the questionnaire
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Self-reporterd quality of life measured by EORTC QLQ-C30 questionnaire
Tijdsspanne: Cross-sectional at time of inclusion, at least 6 months after pelvic exenteration
|
The EORTC QLQ-C30 is a 30-item questionnaire measuring the quality of life (QoL) of cancer patients, developed by the European Organisation for Research and Treatment of Cancer (EORTC).
It assesses physical, psychological, and social functioning.
|
Cross-sectional at time of inclusion, at least 6 months after pelvic exenteration
|
|
Self-reporterd quality of life measured by EORTC QLQ-CX24 questionnaire
Tijdsspanne: Cross-sectional at time of inclusion, at least 6 months after pelvic exenteration
|
The EORTC QLQ-CX24 is a 24-item questionnaire, designed to assess disease-specific and treatment-specific aspects of quality of life in patients with cervical cancer.
It is developed by the European Organisation for Research and Treatment of Cancer (EORTC).
|
Cross-sectional at time of inclusion, at least 6 months after pelvic exenteration
|
|
Self-reported sexuality assessed by the PISQ-12 questionnaire with additional study-specific questions
Tijdsspanne: Cross-sectional at time of inclusion, at least 6 months after pelvic exenteration
|
The PISQ-12 questionnaire is designed for patients with urinary incontinence or pelvic organ prolapse.
However, it also includes useful questions for patients undergoing pelvic exenteration.
In addition, the investigators have developed and included their own questions specifically tailored for patients with a neovagina.
|
Cross-sectional at time of inclusion, at least 6 months after pelvic exenteration
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Genitale ziekten
- Urogenitale neoplasmata
- Neoplasmata per site
- Neoplasmata
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Baarmoeder Ziekten
- Genitale ziekten, vrouw
- Genitale neoplasmata, vrouwelijk
- Baarmoederhalsaandoeningen
- Baarmoeder Neoplasmata
- Vulvaire ziekten
- Vaginale ziekten
- Gedrag
- Seksueel gedrag
- Baarmoeder Cervicale Neoplasmata
- Endometriumneoplasmata
- Vulvaire neoplasmata
- Vaginale neoplasmata
- Seksualiteit
Andere studie-ID-nummers
- R25065
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .